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Abstract 
Background:  The role of plasma glutamine, fish oil and antioxidants concentrations in the treatment effect of 
immune-modulating high-protein versus high-protein enteral nutrition on 6-month mortality in critically ill patients 
is explored, as unexpected negative outcomes of recent large randomized controlled trials on immune-modulating 
nutrients have raised questions about safety of these interventions.
Methods: Post hoc analysis of the MetaPlus randomized controlled trial which was performed in a total of 301 
medical, surgical and trauma critically ill patients in fourteen European intensive care units. Patients received either 
immune-modulating (glutamine, fish oil and antioxidant enriched) high-protein (IMHP) or isocaloric high-protein (HP) 
enteral nutrition. Six-month mortality and baseline, day 4 and day 8 plasma concentrations of glutamine, (eicosapen-
taenoicacid + decosahexaenoicacid)/long-chain fatty acid plasma level ratio ((epa + dha)/lcf ratio), selenium, vitamin 
c, vitamin e and zinc were measured.
Results:  The harmful treatment effect of the IMHP versus HP enteral nutrition on 6-month mortality was only dem-
onstrated in the medical subgroup (HR 2.52, 95% CI 1.36–4.78, P = 0.004). Among medical patients, when corrected 
for age groups and APACHE-II scores, there were no statistically significant associations between baseline plasma 
levels and 6-month mortality, except for zinc (HR 1.06, 95% CI 1.00–1.12, P = 0.026). IMHP feeding resulted in statisti-
cally significant increase in plasma levels of glutamine, vitamin e, vitamin c and (epa + dha)/lcf ratio from baseline to 
day 4, while only the change from baseline to day 4 of (epa + dha)/lcf ratio was statistically significant associated with 
6-month mortality (HR 1.18, 95% CI 1.02–1.35, P = 0.021) and identified as mediator for the harmful treatment effect 
of IMHP enteral nutrition among medical ICU patients.
Conclusion: We hypothesize that the harmful effect of IMHP compared to HP enteral nutrition in a heterogene-
ous group of critically ill patients is limited to the medical critically ill patients and mediated by an early increase in 
(epa + dha)/lcf ratio.
Trial Registration Dutch Trial Register 26 January 2010 (NTR2181 http://www.trialregister.nl/trialreg/admin/rctview.
asp?TC=2181).
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Background
Safety of immune-modulating nutrients like glutamine, 
fish oils and antioxidants to modulate infectious morbid-
ity and enhance recovery from critical illness is under 
debate [1–6]. Recent large randomized trials in ICU 
patients failed to demonstrate benefits of immune-mod-
ulating nutrients and even demonstrated increased mor-
tality [7–11].
Unexpected negative study results raised concern about 
safety of immune-modulating nutrients. It has been sug-
gested that supplementation with immune-modulating 
nutrients should be reserved for specifically identified 
patients with compromised availability and plasma levels 
should be measured before supplementation [5]. How-
ever, low plasma levels could reflect adaptive and benefi-
cial stress responses rather than conditional deficiency. 
The conditional deficiency hypothesis of glutamine has 
been challenged [12], and it has been suggested that 
interfering with a potential adaption could be deleterious 
[3].
This could suggest that supplementation with immune-
modulating nutrients in critically ill patients does not 
improve outcome [3] and for safety reasons any patient 
with multi-organ failure in the ICU should not receive 
immune-modulating nutrients [2].
Studying mortality in critical illness and plasma sta-
tus of immune-modulating nutrients after supplemen-
tation may provide pathophysiological insight and 
potentially facilitate redefinition of practice guidelines 
recommendations.
In the MetaPlus study, immune-modulating high-pro-
tein (IMHP) enteral feeding enriched with glutamine, fish 
oil and antioxidants was compared with standard high-
protein (HP) enteral feeding in critically ill patients, and 
a hazard ratio (HR) of 1.57 (95% CI, 1.03–2.39; P = 0.04) 
was shown for 6-month mortality adjusted for age and 
APACHE-II score comparing IMHP with HP [7]. Uni-
variate analysis suggested that this harmful effect was 
mainly observed among medical patients, although inter-
action between “type of patient” and “treatment” was 
not tested. The MetaPlus study is unique as plasma con-
centrations of glutamine, eicosapentaenoicacid  +  deco-
sahexaenoicacid)/long-chain fatty acid plasma level ratio 
((epa + dha)/lcf ratio), selenium, vitamin c, vitamin e and 
zinc were obtained at baseline (before treatment) and at 
days 4 and 8.
In this post hoc analysis, we address the interaction 
between IMPH versus HP and medical versus non-med-
ical patients and 6-month mortality and subsequently 
associations of baseline plasma levels and changes in 
immune-modulating nutrient plasma levels and 6-month 
mortality.
Materials and methods
Study design, methodology and population have been 
reported previously [7]. The MetaPlus trial was a prospec-
tive, randomized, multicenter, international, double-blind, 
controlled, parallel-group trial. In total, 301 adult mechan-
ically ventilated ICU patients admitted to 14 participating 
ICUs in 4 European countries that were expected to be 
ventilated for >72 h and to require EN for >72 h were 1:1 
randomized to IMHP or HP enteral nutrition, stratified 
per site and type of patient (medical, surgical non-trauma 
patients, trauma-surgical patients and trauma-non-sur-
gical patients). Patients assigned to IMHP received a glu-
tamine, omega-3 fatty acids and antioxidant (selenium, 
vitamin c, vitamin e and zinc)-enriched experimental tube 
feed. Those assigned to HP received an isocaloric/isoni-
trogenous high-protein tube feed (Nutrison Advanced 
Protison, NV Nutricia, Zoetermeer, The Netherlands). 
Patients were fed according to routine practice with rec-
ommendations toward early enteral feeding up to target 
energy requirements of 25  kcal/kg body weight with a 
maximum of 2500 kcal/day. Patients received study formu-
lations during ICU stay for a maximum of 28 days.
The primary endpoint was incidence of new infections. 
Among others, 28 days and 6-month mortality were sec-
ondary parameters. Blood samples were taken at baseline, 
day 4 and day 8 for plasma glutamine, (epa  +  dha)/lcf 
ratio, selenium, vitamin c, vitamin e and zinc levels. Lab-
oratory methods to measure plasma levels of immune-
modulating nutrients are available in the Additional 
file 1: electronic supplement (S1).
Ethics committees and regulatory authorities approved 
the protocol and accompanying documents. The study 
protocol was registered in the Dutch Trial Register on 
January 26, 2010 (NTR2181, http://www.trialregister.nl/
trialreg/admin/rctview.asp?TC=2181).
Post hoc statistical analyses
In this post hoc analysis, Cox proportional hazard regres-
sion models were used to analyze the time until death 
with subjects still alive at 6  months after study entry 
treated as censored cases (the 6-month mortality). Inter-
actions in these models were tested including an interac-
tion term for interaction of “IMHP versus HP group” and 
subsequently “type of patient (medical vs. non-medical)”, 
“gender”, “age groups”, “APACHE-II”, “SOFA-score”, “base-
line plasma glutamine”, “baseline plasma epa  +  dha/lcf 
ratio”, “baseline plasma selenium”, “baseline plasma zinc” 
and “baseline plasma vitamin e”. For interaction tests, the 
criterion was set a P value <0.10.
In case of statistical significant interaction, treatment 
effects on 6-month mortality were tested by Cox pro-
portional hazard regression analysis with “age groups” 
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and “Acute Physiology and Chronic Health Evaluation-
II (APACHE-II) scores” as covariates within each sub-
group. Associations of baseline plasma concentrations 
and 6-month mortality were tested using univariate Cox 
proportional hazard regression and multivariate Cox 
proportional hazard regression with “age groups” and 
“APACHE-II score” as covariates.
Differences between IMHP and HP in plasma concen-
tration changes from baseline to day 4 and from baseline 
to day 8 were analyzed as continuous variables using two-
sample t tests. The criterion was set at P value <0.05.
The relation between plasma nutrient status changes 
and 6-month mortality was evaluated with multivariate 
Cox proportional hazard models for 6-month mortality 
including “age groups”, “APACHE-II score” and “baseline 
plasma nutrient concentrations” as covariates.
To assess which plasma nutrient changes mediated the 
effects on 6-month mortality, the causal steps approach 
was used [13]. This approach requires estimating each 
path depicted in Fig. 1.
Model I in Fig. 1 represents treatment effects of IMHP 
versus HP on 6-month mortality as analyzed using Cox 
proportional hazard regression analysis with “age groups” 
and “APACHE-II score” as covariates. In Model II, changes 
in plasma concentrations are suggested to mediate the 
relationship between treatment (IMHP vs. HP) and out-
come (6-month mortality) when both the A and B asso-
ciation paths are statistically significant present and the C′ 
path association coefficient is closer to zero than in the C 
path in model I.
In Model II, the A path depicts the relation between the 
intervention (IMHP vs. HP) and changes in plasma nutri-
ent status. This was analyzed using two-sample t tests. The 
B path describes the relation between changes in plasma 
nutrient status and 6-month mortality and analyzed using 
multivariate Cox proportional hazard models for 6-month 
mortality including “age groups”, “APACHE-II score” and 
“baseline plasma nutrient concentrations” as covariates. 
The Cox proportional hazard regression model with “age 
groups” and “APACHE-II score” as covariates was used to 
evaluate the C and C’ path, only for potential mediators 
having significant (P < 0.05) associations in both the A and 
B paths. The C’ path is evaluated in a Cox proportional 
hazard regression model including changes in plasma 
nutrient status variables as possible mediators.
Statistical analyses were performed on an intention-to-
treat basis with SAS software, version 9.2 (SAS Institute 
Inc, Cary, USA).
Results
“Type of patient (medical vs. non-medical)” was the only 
factor that interacted with the effect of “treatment group 
(IMHP vs. HP)” (interaction term P = 0.051). Table 1 a/b 
depicts the IMHP versus HP treatment effects among 
medical and non-medical patients, showing a statistically 
significant treatment effect among medical patients with 
a HR of 2.52 (95% CI 1.36–4.78, P = 0.004) and no treat-
ment effect in the non-medical group with an HR of 0.97 
(95% CI 0.54–1.74, P = 0.909).
Associations between baseline plasma concentrations 
and 6-month mortality in all patients and in medical and 
non-medical subgroups are shown in Table  2. Univari-
ate analyses showed statistically significant associations 
between baseline glutamine and 6-month mortality and 
between (epa  +  dha)/lcf ratio and 6-month mortality. 
Baseline zinc plasma concentrations were statistically sig-
nificant associated with 6-month mortality in non-med-
ical patients. However, when corrected for “age groups” 
and “APACHE-II scores,” there were no statistically sig-
nificant associations, except for baseline zinc concentra-
tion and 6-month mortality among medical patients.
Baseline plasma concentrations and plasma concentra-
tions on day 4 and day 8 for IMHP and HP are shown in 
Fig.  2 for the medical and non-medical patients. There 
were no statistical significant differences in baseline con-
centrations between IMHP and HP groups. In medical 
and non-medical patients, the changes in plasma levels 
Fig. 1 Illustration of causal step approach for changes in 
(epa + dha)/lcf plasma level ratio from baseline to day 4 as mediator 
for treatment effect. IMHP immune-modulating high-protein enteral 
nutrition, HP high-protein enteral nutrition, A, B, C, C′ association path. 
Method based on: Baron and Kenny [13]. For mediator analyses, it is 
important not only that a given treatment (IMHP vs. HP) is associated 
with the outcome (6-month mortality), but also that the treatment 
induces changes in mediator plasma concentrations (association 
path A) and that these changes are associated with the outcome 
(association path B). In case a potential mediator is inserted into 
multivariate analysis (Model II), the effect of the treatment (C′) should 
disappear. In other words, the treatment induces statistical significant 
changes in the outcome (6-month mortality increase) through an 
increase in plasma levels, these increases in plasma levels are associ-
ated with the increased 6-month mortality, and this effect is medi-
ated through the treatment and not due to other factors
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from baseline to day 4 and from baseline to day 8 were 
statistically significant larger in IMHP-treated patients 
compared with HP patients for (epa  +  dha)/lcf ratio, 
vitamin e and vitamin c, while plasma glutamine change 
from baseline to day 4 was statistically significant in the 
medical patients (Table 3).
The associations between changes in plasma concen-
trations from baseline to day 4 and day 8 and 6-month 
mortality are shown in Table 4. There is a statistically sig-
nificant positive association of changes in (epa + dha)/lcf 
ratios from baseline to day 4 with 6-month mortality in 
the medical patients, and a statistically significant nega-
tive association of changes in zinc from baseline to day 8 
with 6-month mortality in the non-medical patients.
The change in (epa  +  dha)/lcf ratios from baseline 
to day 4 is a potential candidate for mediator analysis 
as for this parameter IMHP versus HP conferred a sta-
tistically significant increase in plasma concentrations 
(Table  3; Fig.  1 association path A) and a statistically 
significant association between plasma concentration 
changes and 6-month mortality (Table 4; Fig. 1 associa-
tion path B). Mediator analysis showed that a change in 
(epa + dha)/lcf ratio from baseline to day 4 was found to 
be a mediator for the treatment effect of IMHP versus HP 
concerning 6-month mortality, as including change in 
(epa + dha)/lcf ratio from baseline to day 4 into the sta-
tistical model decreased the coefficient of the statistical 
treatment effect on 6-month mortality (coefficient 0.823; 
P value: 0.016) to a non-statistical significant treatment 
effect (coefficient 0.618; P value: 0.291, Fig. 1).
Evaluation of the presence of A and B association 
paths in model II Fig.  1 was based on the criterion P 
value < 0.05. Relaxing this criterion to a P value < 0.15 did 
result in more parameters being investigated as possible 
mediators. However, none of those showed any sugges-
tion for a mediating effect (data not shown).
Additional analysis on the association between the 
mediator (epa  +  dha)/lcf ratio and 6-month mor-
tality showed that patients with an increase (≥0) in 
(epa + dha)/lcf plasma level ratios compared with those 
with a decrease (<0) from baseline to day 4 demonstrated 
higher 6-month mortality risk (P  =  0.007, HR  =  2.8) 
(Table 5).
Discussion
Based on this post hoc analysis of the MetaPlus pro-
spective randomized double-blind multicenter trial in 
which a high-protein enteral nutrition enriched with 
immune-modulating nutrients was compared with a 
standard isocaloric isonitrogenous high-protein enteral 
nutrition in a heterogeneous mechanically ventilated 
ICU population, we hypothesize that the harmful treat-
ment effect of IMHP versus HP on 6-month mortality is 
specific for medical patients and that this harmful effect 
is mediated by an acute increase from baseline to day 4 
in plasma (epa + dha)/lcf ratios as: (1) IMHP versus HP 
treatment results in a statistically significant increase in 
plasma (epa  +  dha)/lcf ratios at day 4, (2) an increase 
in (epa  +  dha)/lcf ratios was shown to be associated 
with 6-month mortality, and (3) including changes in 
(epa + dha)/lcf ratios from baseline to day 4 into the sta-
tistical model decreased the coefficient of the statistical 
treatment effect on 6-month mortality to a non-statistical 
significant treatment effect.
Table 1 Multivariate Cox proportional hazard regression analysis on  treatment effects among  medical patients (a) 
and non-medical patients (b)
IMHP immune-modulating high-protein enteral nutrition, HP high-protein enteral nutrition, age group 1 age ≤50 year, age group 2 age 51–70 years, age group 3 age 
71–80 years, age group 4 age >80 years, APACHE-II acute physiology and chronic health evaluation-II
Parameter Parameter estimate Standard error Hazard ratio 95% CI of the hazard ratio P value
1a: Medical patients (n = 109)
IMHP versus HP 0.922 0.319 2.515 [1.360, 4.783] 0.004
Age group 1 versus 4 −2.651 0.788 0.071 [0.011, 0.275] <0.001
Age group 2 versus 4 −1.439 0.393 0.237 [0.110, 0.522] <0.001
Age group 3 versus 4 −1.120 0.409 0.326 [0.145, 0.733] 0.006
APACHE-II score 0.017 0.019 1.017 [0.980, 1.057] 0.376
2a: Non-medical patients (n = 192)
IMHP versus HP −0.034 0.296 0.967 [0.540, 1.736] 0.909
Age group 1 versus 4 −1.595 0.533 0.203 [0.068, 0.562] 0.003
Age group 2 versus 4 −1.489 0.434 0.226 [0.095, 0.531] <0.001
Age group 3 versus 4 −0.467 0.381 0.627 [0.299, 1.353] 0.219
APACHE-II score 0.101 0.026 1.106 [1.052, 1.165] <0.001






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fig. 2 Boxplot figures representing the plasma concentration values and variations of the immune-modulating nutrients at baseline, day 4 and day 
8 among medical and non-medical patients. a Glutamine. b (epa + dha)/lcf ratio. c Selenium. d Vitamin e. e Vitamin c. f Zinc. IMHP immune-modu-
lating high-protein enteral nutrition, HP high-protein enteral nutrition. Boxplot interpretation: 0 or +: average value, −: median, rectangle bottom: 
quartile 1 cutpoint (25th percentile), rectangle upper: quartile 3 cutpoint (75th percentile). 0 or +: outliers more than 1.5 times inter quartile range 
above quartile 3 or below quartile 1, T: highest or lowest level not being an outlier
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Table 3 Baseline plasma concentrations of immune-modulating ingredients and changes from baseline on day 4 and 8 
in medical and non-medical critically ill patients
Immune-modulating nutrient concentrations IMHP (n = 54) mean (SD) HP (n = 55) mean (SD) P value
3a: Medical patients (n = 109)
Glutamine (μmol/L)
 Baseline (BL) 393 (155) 406 (168) 0.687
 Day 4—BL 102 (141) 36 (141) 0.017
 Day 8—BL 77 (148) 10 (168) 0.070
(epa + dha)/lcf ratio (×10−2)
 Baseline 2.5 (1.1) 2.5 (1.1) 0.948
 Day 4—BL 3.3 (2.1) −0.4 (0.5) <0.001
 Day 8—BL 5.3 (2.2) −0.7 (0.7) <0.001
Selenium (μmol/L)
 Baseline 0.84 (0.37) 1.08 (1.00) 0.113
 Day 4—BL 0.16 (0.33) −0.16 (1.08) 0.057
 Day 8—BL 0.21 (0.43) −0.08 (1.26) 0.200
Vit E (μmol/L)
 Baseline 20.3 (7.6) 22.1 (7.2) 0.208
 Day 4—BL 19.5 (13.9) 2.5 (6.3) <0.001
 Day 8—BL 29.1 (18.8) 5.7 (8.9) <0.001
Vit C (μmol/L)
 Baseline 11.1 (14.0) 15.6 (22.0) 0.245
 Day 4—BL 13.6 (17.5) −4.4 (21.9) <0.001
 Day 8—BL 19.7 (18.5) −5.6 (26.3) <0.001
Zinc (μmol/L)
 Baseline 8.09 (6.05) 7.06 (4.05) 0.321
 Day 4—BL 0.73 (4.17) 1.56 (3.56) 0.308
 Day 8—BL 2.09 (3.90) 3.66 (4.34) 0.119
Immune-modulating nutrient concentrations IMHP (n = 98) mean (SD) HP (n = 94) mean (SD) P value
3b Non-medical patients (n = 192)
Glutamine (μmol/L)
 Baseline (BL) 350 (163) 327 (104) 0.252
 Day 4—BL 55 (180) 27 (118) 0.206
 Day 8—BL 16 (191) 30 (137) 0.586
(epa + dha)/lcf ratio (×10−2)
 Baseline 2.5 (1.0) 2.7 (0.9) 0.226
 Day 4—BL 3.5 (2.2) −0.2 (0.6) <0.001
 Day 8—BL 5.0 (2.7) −0.4 (0.6) <0.001
Selenium (μmol/L)
 Baseline 0.99 (0.46) 0.99 (0.55) 0.928
 Day 4—BL 0.13 (0.59) 0.03 (0.56) 0.272
 Day 8—BL 0.17 (0.73) 0.15 (0.68) 0.900
Vit E (μmol/L)
 Baseline 19.6 (6.6) 20.5 (8.2) 0.399
 Day 4—BL 19.7 (13.9) 3.3 (5.8) <0.001
 Day 8—BL 26.7 (14.4) 6.6 (7.5) <0.001
Vit C (μmol/L)
 Baseline 9.7 (8.2) 9.8 (7.7) 0.904
 Day 4—BL 7.0 (13.2) −2.1 (6.3) <0.001
 Day 8—BL 11.6 (14.7) −0.2 (9.3) <0.001
Zinc (μmol/L)
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Medical versus non-medical patients
The debate regarding safety of supplementation of 
immune-modulating nutrients has mainly emerged from 
negative results of the REDOXs [9] and OMEGA [10] tri-
als with, respectively, 80 and 85% medical ICU patients, 
while in the SIGNET trial [8], showing no benefit nor 
harm of immune-modulating nutrients, only 25% of 
included patients were medical. Meta-analyses of results 
of immune-modulating nutrient intervention studies 
among surgical patients have not reported any harmful 
effects and even show positive effects [14, 15]. Our post 
hoc analyses suggest harmful treatment effects of IMHP 
on 6-month mortality among medical patients and not 
among non-medical patients, and are in line with these 
observations. Medical patients were older, had higher 
APACHE-II scores and more frequently suffered from 
sepsis and pulmonary diseases [7]. Previously, it was rec-
ommended not to use arginine in ICU patients [16] or 
patients with severe sepsis [17] due to possible vasodila-
tory effects from NO production in patients with circula-
tory shock. This mechanism might have played a role as 
glutamine serves as precursor for de novo arginine pro-
duction through the citrulline–arginine pathway [18].
Consequences for the glutamine debate
Our results show positive associations between higher 
baseline plasma glutamine and increased 6-month mor-
tality in all patients and in non-medical patients. These 
findings contradict the hypothesis that glutamine is a 
conditional essential amino acid during critical illness [5].
This hypothesis is mainly based on one study from 2001 
showing that ICU patients with plasma glutamine levels 
below 420 µmol/L show increased hospital mortality com-
pared with patients with higher levels (420 µmol/L) [19]. 
However, mean age in the low glutamine group (74 years) 
was statistically significant different compared to the high 
glutamine group (63 years). Age was not included in the 
hospital mortality logistic regression analysis as sepa-
rate explanatory factor. Including age potentially could 
have changed the strength and direction of associations, 
as in the MetaPlus study we showed that age is a strong 
independent mortality predictor [7] and our present 
analysis demonstrates that including age group covariates 
markedly influences associations between baseline lev-
els and 6-month mortality. Recently, it was shown that 
not only low ICU admission plasma glutamine levels 
(<420  µmol/L), but also high plasma glutamine levels 
(>930  µmol/L) were associated with increased 6-month 
mortality, suggesting a U-shaped relation between plasma 
glutamine and 6-month mortality [20]. Furthermore, in 
septic patients, non-survivors had statistically significant 
higher median plasma glutamine levels (648  µmol/L) 
compared to survivors (460  µmol/L) [21]. In the Meta-
Plus study, only 2 patients had plasma levels >930 µmol/L 
and 95% confidence intervals of baseline plasma glu-
tamine levels were 339–391  µmol/L (IMHP group) and 
334–378 µmol/L (HP group)[7], suggesting the univariate 
positive association between baseline glutamine concen-
tration and 6-month mortality is not influenced markedly 
by very high baseline concentrations.
The REDOXs trial showed increased mortality with 
glutamine supplementation and raised questions whether 
critical illness is associated with low plasma glutamine 
levels at all [2] and whether interfering with glutamine 
supplementation could be deleterious [3].
Our post hoc analysis does not show associations 
between changes in plasma glutamine and 6-month 
mortality. Moreover, changes in plasma glutamine con-
centrations were not found to be a mediator of harmful 
treatment effects of IMHP versus HP in medical patients. 
Therefore, our post hoc analyses do not support the 
hypothesis that interfering with glutamine supplementa-
tion in medical critically ill patients is deleterious. How-
ever, this should be interpreted with caution and it may 
not be concluded that glutamine is not harmful as the 
enteral dose of glutamine supplementation and the effect 
of IMHP on glutamine levels were very modest. Further-
more, plasma glutamine levels, independent of the treat-
ment allocation, were very comparable in both groups as 
seen in Fig. 2.
Consequences for the epa and dha debate
This post hoc analysis is the first to suggest that a change 
from baseline to day 4 in (epa  +  dha)/lcf plasma level 
ratios has a positive association with 6-month mortal-
ity risk. Average plasma (epa  +  dha)/lcf ratios among 
Table 3 continued
Immune-modulating nutrient concentrations IMHP (n = 98) mean (SD) HP (n = 94) mean (SD) P value
 Baseline 6.18 (3.25) 6.24 (3.76) 0.907
 Day 4—BL 1.20 (3.13) 1.36 (3.85) 0.754
 Day 8—BL 3.98 (4.59) 3.44 (6.39) 0.538
All tests were performed with two-sample t tests
IMHP immune-modulating high-protein enteral nutrition, HP high-protein enteral nutrition, sd standard deviation, (epa + dha)/lcf ratio 
(eicosapentaenoicacid + decosahexaenoicacid)/long-chain fatty acid plasma level ratio, BL baseline, Day 4—BL change in plasma concentration from baseline to day 
4, Day 8—BL change in plasma concentration from baseline to day 8
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healthy persons across 16 European regions vary from 
3.4 to 8.9%, due to differences in food intake [22]. In our 
study, average ICU admission values were below this 
range (2.5%), while after supplementation with IMHP for 
4 or 8  days, averages were within these ranges. Among 
HP supplemented patients receiving no epa or dha, aver-
ages remained low, or even slightly decreased, suggesting 
a fast response of plasma status on epa and dha sup-
plementation in IMHP patients. In the OMEGA study 
among acute lung injury ICU patients, Rice showed fast 
increases in plasma status within 3 days in epa, dha and 
gamma-linolenic-supplemented patients [10]. Rice con-
cluded that fish oil supplementation might be harmful as 
illustrated by higher risk of 60-day mortality. Critics of 
the OMEGA trial suggested that twice daily bolus admin-
istration and higher protein intake in control patients 
confounded results [4]. However, our present results 
suggest that increased 6-month mortality in the IMHP 
group versus the HP group with similar amounts of pro-
tein was mediated through increases in (epa +  dha)/lcf 
ratios from baseline to day 4 during continuous feed-
ing. Therefore, without the perceived limitations of the 
OMEGA trial, we now report similar hazardous effects 
of omega-3 fatty acids supplementation among medical 
critically ill patients. Consequently, our findings do not 
support suggested clinical benefits of omega-3 fatty acids 
in enteral nutrition to preserve immune function and 
prevent aspects of the inflammatory response [23], as 
we did not observe any benefits on infectious morbidity 
[7]. As we did not measure biomarkers of immune func-
tion or inflammation, we cannot rule out that immune 
stimulation or anti-inflammatory effects have occurred. 
However, in the OMEGA trial no reductions in levels of 
inflammatory biomarkers despite marked increases in 
plasma omega-3 fatty acids were observed. The mecha-
nism why increases in plasma omega-3 fatty acids are 
associated with increased mortality in medical critically 
ill patients remains unclear. We speculate that due to 
the suggested anti-inflammatory effect of fish oil IMHP 
not only reduced the systemic inflammatory response 
but also enhanced the compensatory anti-inflammatory 
response syndrome (CARS). It has become apparent that 
CARS is not simply a consecutive response to SIRS and 
hyperinflammation, but that both responses may occur 
simultaneously in the early phase after ICU admission. 
Possibly, we have induced the so-called persistent inflam-
matory immunosuppressed catabolic syndrome (PICS) 
in these patients [24]. Another speculation is based on 
interesting data on omega-3 fatty acids supplementation 
during exercise in healthy volunteers showing reduced 
maximal power output by 10% and maximal heart rate 
by 6% within 1–3  days of supplementation [25]. These 
negative cardiovascular and metabolic effects of omega-3 
fatty acids supplementation during exercise probably are 
mediated by other mechanisms than omega-3 fatty acids 
incorporation into plasma membranes [25].
Consequences for the antioxidant debate
Recent guidelines on nutritional support for critically 
ill patients by the Society of Critical Care Medicine and 
American Society of Parenteral and Enteral Nutrition 
indicate very low evidence for routine supplementation 
Table 5 Associations between changes in (epa + dha)/lcf ratio from baseline to day 4 and 6-month mortality in medical 
critically ill patients
Coef coefficient. The coefficient is the Cox proportional hazard regression parameter estimate; a positive coefficient indicates a worse prognosis, and a negative 
coefficient indicates a protective effect of the variable on 6-month mortality. Coefficient values represent changes per percentage for (epa + dha)/lcf ratio. SE is the 
parameter estimate standard regression. P values represent Chi-square statistic testing the null hypothesis that the estimate is zero
(epa + dha)/lcf ratio parameters 6-months mortality Cox proportional hazard model analysis
Incidence (%) Coef. SE Hazard ratio 95% CI of the hazard ratio P value
(epa + dha)/lcf ratio (×10−2), continu-
ous
0.162 0.070 1.176 [1.023, 1.348] 0.021
(epa + dha)/lcf ratio (×10−2), recoded 
to quartiles
 Q1 cutpoint: <−0.44 33 Q1 versus Q4 −0.667 0.486 0.513 [0.191, 1.324] 0.170
 Q2 cutpoints: ≥−0.44 to <0.11 35 Q2 versus Q4 −0.960 0.506 0.383 [0.137, 1.023] 0.058
 Q3 cutpoints: ≥0.11 to <3.19 48 Q3 versus Q4 0.076 0.447 1.079 [0.447, 2.627] 0.865
 Q4 cutpoint: ≥3.19 46
Overall 0.105
(epa + dha)/lcf ratio (×10−2), recoded 
to ≥0 versus <0
 <0 34 ≥ 0 versus <0 1.030 0.383 2.800 [1.344, 6.098] 0.007
 ≥0 46
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of antioxidants summarizing studies until 2013 [26]. 
In these guidelines, it is indicated that antioxidant and 
trace element supplementation is associated with sig-
nificant reductions in overall mortality. Recent REDOXs 
and Signet trials did not show any benefit or harm from 
antioxidant supplementation, but a recent retrospective 
study on selenium supplementation in postoperative ICU 
patients with sepsis showed increased mortality in uni-
variate analysis [11]. Our post hoc analyses show posi-
tive associations with baseline zinc concentrations and 
6-month mortality in medical patients. However, there 
was no effect of IMHP versus HP treatment on plasma 
zinc levels and no association between increase in plasma 
zinc concentrations and 6-month mortality, with similar 
results for selenium, vitamin e and vitamin c. Therefore, 
we hypothesize that harmful effects of IMHP versus HP 
treatment is not due to these antioxidants.
To the best of our knowledge, the Metaplus study 
provides the largest database to study effects of nutri-
tional treatment on plasma concentrations of immune-
modulating nutrients in a heterogeneous mechanically 
ventilated ICU population. Although our data suggest 
mediator effects of changes in plasma (epa  +  dha)/lcf 
ratio, we must consider that findings are based on results 
from unplanned post hoc analyses. Furthermore, the 
relationship could be associative without direct causality 
if an underlying unknown confounding factor is involved. 
The intervention was a cocktail of various immune-mod-
ulating nutrients and may confer positive or negative 
effects on mortality, with or without interaction. Further-
more, post hoc analyses only generate hypotheses and 
therefore preclude firm recommendations.
Conclusions
We hypothesize that the harmful effect of immune-mod-
ulating high-protein enteral nutrition compared to high-
protein enteral nutrition in the MetaPlus trial studying 
a heterogeneous group of critically ill patients is limited 
to the medical critically ill patients and mediated by an 
early increase in (eicosapentaenoicacid  +  decosahexae-
noicacid)/long-chain fatty acid plasma ratio, resulting in 
increased 6-month mortality.
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